

PHARMACY POLICY STATEMENT Ohio Medicaid				
DRUG NAME	Nucala (mepolizumab)			
BILLING CODE	Medical: J2182 (1 unit = 1 mg)			
BENEFIT TYPE	Medical			
SITE OF SERVICE ALLOWED	Home/Office/Outpatient Hospital			
COVERAGE REQUIREMENTS	Prior Authorization Required (Non			

Nucala (mepolizumab) will be considered for coverage under the medical benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

HYPEREOSINOPHILIC SYNDROME (HES)

For initial authorization:

- 1. Member must be 12 years of age or older; AND
- 2. Medication must be prescribed by or in consultation with an immunologist, allergist, or hematologist; AND
- 3. Member has diagnosis of HES; AND
- 4. Member has a documented blood eosinophil count of >1500 cells/ μL; AND
- 5. Member has trialed and failed Glucocorticoids for at least one month; AND
- 6. Member has a history of 2 or more HES flares within the past year defined as worsening of clinical signs and symptoms or increasing eosinophils requiring an escalation in therapy; AND
- 7. Member does not have either of the following:
 - a) Identifiable non-hematologic secondary cause (i.e., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy);



- 2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT00287391, A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis; 2018 Jan 26. Available at: https://clinicaltrials.gov/ct2/show/NCT02020889?term=mepolizumab&recrs=e&rank=9.
- 3. Wechsler ME, Akuthota P, Jayne D, et al. EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079.
- 4. Matteson EL. Eosinophilic Granulomatosis with Polyangiitis (EGPA/Churg-Strauss Syndrome). Vascuiltis Foundation. Available at: <a href="https://www.vasculitisfoundation.org/education/forms/eosinophilic-granulomatosis-with-polyangiitis-churgestraussesyndromatosis-with-polyangiitis-churgestrausse